Molecure S.A. (WSE:MOC)

Market Cap	171.73M
Revenue (ttm)	2.92M
Net Income (ttm)	-31.29M
Shares Out	20.20M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	85.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,356
Average Volume	18,921
Open	8.50
Previous Close	8.50
Day's Range	8.37 - 8.60
52-Week Range	7.60 - 16.70
Beta	2.61
RSI	50.67
Earnings Date	Apr 30, 2025

About Molecure

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 102
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MOC

Financial Performance

In 2024, Molecure's revenue was 2.92 million, a decrease of -20.08% compared to the previous year's 3.65 million. Losses were -31.29 million, 10.3% more than in 2023.